Rafael Madero-Marroquin

5PUBLICATIONS
36CO-AUTHORS
Gene and molecular therapyHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 02, 2026
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

|Jun 16, 2025
Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax Therapy.

Rafael Madero-Marroquin, Joseph Cannova, Emily Dworkin

|Jan 27, 2025
CD58 expression does not impact response to inotuzumab ozogamicin in patients with B-cell acute lymphoblastic leukemia.

Rafael Madero-Marroquin, Ryan W Hunter, Caner Saygin

|Mar 05, 2024
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy.

Rafael Madero-Marroquin, Emily Dworkin, Howard Weiner

|Dec 11, 2023
Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors.

Rafael Madero-Marroquin, Adam S DuVall, Caner Saygin

Pageof 1

Frequent Collaborators

4 joint publications

Anand Ashwin Patel

1 joint publications

Curtis A Lachowiez

1 joint publications

Joshua F Zeidner

1 joint publications

Jad Othman